NLS Pharmaceutics Ltd. Shareholders Approve Agenda Items, Elect New Auditor
Ticker: NCEL · Form: 6-K · Filed: Aug 15, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting, auditor-change
TL;DR
NLS Pharma shareholders approved all items, including a new auditor, on June 27, 2024.
AI Summary
On June 27, 2024, NLS Pharmaceutics Ltd. held an ordinary shareholders' meeting where all proposed agenda items were approved, including the election of a new statutory auditor in Switzerland. The company also announced its intention to replace its statutory auditor.
Why It Matters
This filing indicates a change in corporate governance and oversight for NLS Pharmaceutics Ltd., which could impact investor confidence and regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a routine corporate update regarding a shareholder meeting and auditor change, with no immediate financial or operational risks indicated.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- June 27, 2024 (date) — Date of shareholders' meeting
FAQ
What was the date of the ordinary shareholders' meeting for NLS Pharmaceutics Ltd.?
The ordinary shareholders' meeting was convened on June 27, 2024.
Were all agenda items approved at the shareholders' meeting?
Yes, all agenda items were approved as originally proposed.
What significant change was approved at the meeting regarding the company's oversight?
The election of a new statutory auditor in Switzerland was approved.
What is the principal executive office address of NLS Pharmaceutics Ltd.?
The address is The Circle 6, CH-8058 Zurich, Switzerland.
Does NLS Pharmaceutics Ltd. file annual reports under Form 20-F or 40-F?
NLS Pharmaceutics Ltd. files annual reports under Form 20-F.
Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 16.5 · Accepted 2024-08-15 16:02:03
Filing Documents
- ea0211447-6k_nlspharma.htm (6-K) — 16KB
- ea021144701ex16-1_nlspharma.htm (EX-16.1) — 3KB
- ex16-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-069614.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: August 15, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3